Shire has divested a cell therapy program for angina it picked up via the acquisition of Baxalta in 2016; Caladrius hopes to bring the Phase III treatment to the US market soon.
Caladrius Biosciences Inc., a clinical-stage biopharma developing therapies for autoimmune and select cardiology indications, has acquired from Shire PLC a late-stage cell therapy program for refractory angina.
Caladrius has purchased the exclusive worldwide development and regulatory rights for Shire's CD34+ cell therapy program for the treatment of...
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis
SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.
